Organon & Co.
- Last sale
- Nov 12, 2026 · +0.07%
- Market cap
- $3.65B
- 262.62M shares
- Filings
- 466
Q3 2026−2.9% FY25 yoy
Q3 2026−78.4% FY25 yoy
—
—
—Q3 2026derived−29.6% FY25 yoy
Q3 2026−78.4% FY25 yoy
Q3 2026−15.0% FY25 yoy
- $3.65B
- 17.1×
- 0.6×
- 3.1×
- 18.49%
- 0.55%
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $6,216,000,000 | reported | |
| FY 2024 | 2024-12-31 | $6,403,000,000 | reported | |
| FY 2023 | 2023-12-31 | $6,263,000,000 | reported | |
| FY 2022 | 2022-12-31 | $6,174,000,000 | reported | |
| FY 2021 | 2021-12-31 | $6,304,000,000 | reported | |
| FY 2020 | 2020-12-31 | $6,532,000,000 | reported | |
| FY 2019 | 2019-12-31 | $7,777,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $88.00M | — | $88.00M | $0.34 | 260.32M sh | +0.9% | 16.4% |
| FY2024 | $297.00M | — | $297.00M | $1.12 | 257.95M sh | +0.9% | 38.9% |
| FY2023 | $294.00M | — | $294.00M | $1.12 | 255.64M sh | +0.5% | 53.6% |
| FY2022 | $290.00M | — | $290.00M | $1.12 | 254.38M sh | +0.3% | 43.8% |
| FY2021 | $145.00M | — | $145.00M | $0.56 | 253.64M sh | — | 7.4% |
Segments
LineFY2025ShareChange
Europe and Canada$1.62B26%−8.2%
U.S.$1.60B26%+2.0%
Latin America, Middle East, Russia, and Africa$1.07B17%+3.7%
Asia Pacific and Japan$1.00B16%−4.8%
China$829.00M13%−2.1%
Other$93.00M1.5%−32.1%
Total$6.22B
Pharmaceutical preparations
Organon & Co. is the 16th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
BHCBausch Health Companies Inc.$10.3B6.7%1.5%$3.1BZTSZoetis Inc.$9.5B2.3%28.2%$33.7B
OGNOrganon & Co. (this company)$6.2B2.9%3.0%$3.7B
ONCBeOne Medicines Ltd.$5.3B40.2%5.4%$617.8BELANElanco Animal Health Inc$4.7B6.2%4.9%$13.3BJAZZJazz Pharmaceuticals plc$4.3B4.9%8.3%$15.4BPRGOPerrigo Co PLC$4.3B2.8%33.5%$2.2BGMABGenmab A/S$3.7B19.2%25.9%—ALNYAlnylam Pharmaceuticals, Inc.$3.7B65.2%8.4%$21.0BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Organon & Co. · CIK 1821825 · Engraved from SEC EDGAR